Efficacy and safety of immune checkpoint inhibitors plus chemotherapy in esophageal cancer patients with liver metastases

Table 4 Comparison of treatment-related adverse events between the two groups, n (%)

TRAEs	Total number of cases (n = 126)	CMT group (n = 87)	CMT + ICI group (n = 39)	χ² value	P value
Any TRAEs	116 (92.1)	80 (92.0)	36 (92.3)	0.000	1.000
TRAEs ≥ 10%
Hematologic toxicity	112 (88.9)	76 (87.4)	36 (92.3)	0.261	0.609
Anemic	104 (82.5)	71 (81.6)	33 (84.6)	0.169	0.681
Leucopenia	71 (56.3)	49 (56.3)	22 (56.4)	0.000	0.993
Neutropenia	57 (45.2)	40 (46.0)	17 (43.6)	0.062	0.803
Thrombocytopenia	52 (41.3)	33 (37.9)	19 (48.7)	1.293	0.256
Hypoalbuminemia	71 (56.3)	50 (57.5)	21 (53.8)	0.144	0.704
Liver dysfunction	40 (31.7)	32 (36.8)	8 (20.5)	3.289	0.070
Increased γ-GT	15 (11.9)	13 (14.9)	2 (5.1)	1.626	0.202
Increased AST	21 (16.7)	16 (18.4)	5 (12.8)	0.602	0.438
Nausea and vomiting	43 (34.1)	35 (40.2)	8 (20.5)	4.657	0.031a
Fatigue	36 (28.6)	25 (28.7)	11 (28.2)	0.004	0.951
≥ 3 TRAEs	41 (32.5)	32 (36.8)	9 (23.1)	2.304	0.129
Hematologic toxicity	37 (29.4)	28 (32.2)	9 (23.1)	1.077	0.299
Neutropenia	17 (13.5)	14 (16.1)	3 (7.7)	1.628	0.202

^aP < 0.05, statistical significance in pairwise multiple comparisons between two groups.

CMT: Chemotherapy; ICI: Immune checkpoint inhibitor; TRAEs: Treatment-related adverse events; γ-GT: Gamma-glutamyl transferase; AST: Aspartate aminotransferase.